This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilars & Animal Health. Check out our full report below:  

Incyte Highlights P-III (TRuE-PN) Clinical Program Data of Opzelura (1.5% Ruxolitinib Cream) for Prurigo Nodularis (PN) at AAD 2025 

Read More: Incyte 

Johnson & Johnson Highlights P-III Clinical Data of Icotrokinra for Plaque Psoriasis at AAD 2025 

Read More: J&J 

Novo Nordisk Reveals P-III (REDEFINE 2) Trial data of CagriSema for Weight Loss in Obese/Overweight and T2D Patients 

Read More: Novo Nordisk 

Eli Lilly and Incyte Highlight P-III (BRAVE-AA-PEDS) Trial Data of Baricitinib for Alopecia Areata at AAD 2025 

Read More: Eli Lilly and Incyte 

Arvinas & Pfizer Reports Topline Data from P-III (VERITAC-2) Trial of Vepdegestrant for Breast Cancer 

Read More: Arvinas & Pfizer 

Merck Reports P-III (MK-8591A-052 & MK-8591A-051) Trial Data of Doravirine + Islatravir (DOR/ISL) for HIV-1 Infection in Adults 

Read More: Merck 

The EC Approves BMS’ Opdivo + Yervoy as 1L Treatment for Hepatocellular Carcinoma 

Read More: BMS 

AstraZeneca and Ionis’ Wainzua (Eplontersen) Receives the EC’s Approval to Treat Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy 

Read More: AstraZeneca and Ionis 

China’s NMPA Approves Kelun-Biotech's Sacituzumab Tirumotecan (sac-TMT) for EGFR-mutant NSCLC 

Read More: Kelun-Biotech 

Geron Receives the EC’s Approval for Rytelo (Imetelstat) to Treat Transfusion-Dependent Anemia due to Lower-Risk MDS 

Read More: Geron 

China’s NMPA Accepts BLA of Zai Lab’s Tivdak for Recurrent or Metastatic Cervical Cancer 

Read More: Zai Lab 

Otsuka and Lundbeck Receive the EC’s Approval for Rxulti to Treat Schizophrenia in Adolescents 

Read More: Otsuka and Lundbeck 

Nosis Biosciences Partners with Janssen Biotech for Cell-Targeted RNA Drugs 

Read More: Nosis Biosciences and Janssen Biotech 

Pierre Fabre Laboratories and RedRidge Bio Enter R&D Collaboration & License Agreement for Biparatopic Antibody (BPA) Candidates 

Read More: Pierre Fabre Laboratories and RedRidge Bio 

Ono Pharma and Ionis Enter into License Agreement for Sapablursen to Treat Polycythemia Vera 

Read More: Ono Pharma and Ionis 

Zealand Pharma and Roche enter a ~$5.3B Deal to Co-Develop and Commercialize Petrelintide for Weight Management 

Read More: Zealand Pharma and Roche 

The US FDA Grants 510(k) Clearance to Zimmer Biomet’s Persona Revision SoluTion Femur 

Read More: Zimmer Biomet 

Beckman Coulter Receives the US FDA 510(k) Clearance For DxC 500i Clinical Analyzer 

Read More: Beckman Coulter 

J&J MedTech Reports the US FDA‘s 510(k) Clearance of MONARCH QUEST for Robot-Assisted Bronchoscopy 

Read More: J&J MedTech 

Sun Pharma to Acquire Checkpoint Therapeutics For ~$355M 

Read More: Sun Pharma & Checkpoint Therapeutics 

Celltrion’s Omlyclo (Biosimilar, Xolair) Secures the US FDA’s Approval 

Read More: Celltrion 

Celltrion launches SteQeyma (Biosimilar, Stelara) in the US 

Read More: Celltrion 

Antech Launches trūRapid FOUR For Canine Vector-Borne Disease Screening 

Read More: Antech 

Kemin Industries Launches Prosidium to Improve Biosecurity in Animal Feed Industry & Supply 

Read More: Kemin Industries 

Related Post: PharmaShots Weekly Snapshots (March 03, 2025 – March 07, 2025)